1. Home
  2. REGN vs COR Comparison

REGN vs COR Comparison

Compare REGN & COR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • COR
  • Stock Information
  • Founded
  • REGN 1988
  • COR 2001
  • Country
  • REGN United States
  • COR United States
  • Employees
  • REGN N/A
  • COR N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • COR Other Pharmaceuticals
  • Sector
  • REGN Health Care
  • COR Health Care
  • Exchange
  • REGN Nasdaq
  • COR Nasdaq
  • Market Cap
  • REGN 59.5B
  • COR 57.4B
  • IPO Year
  • REGN 1991
  • COR N/A
  • Fundamental
  • Price
  • REGN $576.66
  • COR $319.60
  • Analyst Decision
  • REGN Buy
  • COR Buy
  • Analyst Count
  • REGN 23
  • COR 11
  • Target Price
  • REGN $795.04
  • COR $311.91
  • AVG Volume (30 Days)
  • REGN 1.2M
  • COR 1.5M
  • Earning Date
  • REGN 10-28-2025
  • COR 11-05-2025
  • Dividend Yield
  • REGN 0.61%
  • COR 0.69%
  • EPS Growth
  • REGN 5.03
  • COR 5.07
  • EPS
  • REGN 39.67
  • COR 9.68
  • Revenue
  • REGN $14,214,200,000.00
  • COR $316,654,371,000.00
  • Revenue This Year
  • REGN N/A
  • COR $10.30
  • Revenue Next Year
  • REGN $4.74
  • COR $6.52
  • P/E Ratio
  • REGN $14.53
  • COR $33.05
  • Revenue Growth
  • REGN 5.38
  • COR 11.56
  • 52 Week Low
  • REGN $476.49
  • COR $223.92
  • 52 Week High
  • REGN $1,024.36
  • COR $320.37
  • Technical
  • Relative Strength Index (RSI)
  • REGN 51.13
  • COR 66.17
  • Support Level
  • REGN $541.00
  • COR $313.58
  • Resistance Level
  • REGN $577.17
  • COR $319.87
  • Average True Range (ATR)
  • REGN 19.79
  • COR 6.24
  • MACD
  • REGN -1.32
  • COR 1.08
  • Stochastic Oscillator
  • REGN 46.31
  • COR 96.85

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About COR Cencora Inc.

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Share on Social Networks: